RT Conference Proceedings
T1 Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study
A1 Leighl, N. B.
A1 Shu, C. A.
A1 Minchom, A.
A1 Felip, E.
A1 Cousin, S.
A1 Cho, B. C.
A1 Park, K.
A1 Han, J-Y.
A1 Boyer, M.
A1 Lee, C. K.
A1 Moreno Garcia, V.
A1 Tomasini, P.
A1 Viteri, S.
A1 Xie, J.
A1 Mertz, J.
A1 Artis, E.
A1 Schnepp, R. W.
A1 Knoblauch, R. E.
A1 Thayu, M.
A1 Trigo Perez, J. M.
PB Elsevier
SN 0923-7534
YR 2021
FD 2021-09-21
LK https://hdl.handle.net/10668/26937
UL https://hdl.handle.net/10668/26937
LA en
DS RISalud
RD Apr 7, 2025